|
**Overview**: Human Leukocyte Antigen DSA Class I and II Panel**Introduction**: The Human Leukocyte Antigen DSA Class I and II Panel is a diagnostic tool designed to detect donor-specific antibodies using serum samples. In India, DSA (donor-specific anti-HLA antibodies) are a major cause of antibody-mediated rejection in kidney transplantation (~20-30 percent of graft losses), especially in sensitized patients (prior transplant, transfusion, pregnancy). High morbidity from under-testing in rural/low-SES transplant recipients, limited transplant immunology labs, delayed DSA monitoring leading to chronic rejection or graft failure. Per immunology practices aligned with ICMR and Indian Society of Organ Transplantation guidelines, the test employs immunoassay (single antigen bead/Luminex) for DSA Class I and Class II, antibody specificity, and quantitative result over 1-2 days with high sensitivity/specificity, valuable for pre- and post-transplant risk stratification. This diagnostic falls under transplant screening and targets sensitized recipients or those with graft dysfunction, addressing accurate detection to guide desensitization, augmented immunosuppression, or retransplant planning. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise DSA profiling and improving long-term graft survival. Its serum-based approach ensures reliable antibody identification.**Other Names**: HLA DSA Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: DSA single antigen bead standard; in India, expanding in transplant centers.**Purpose**: The test assesses 4 parameters including DSA Class I to guide transplant rejection risk assessment, detect donor-specific antibodies, inform therapy.**Test Parameters**: 1. DSA Class I, 2. DSA Class II, 3. Antibody Specificity, 4. Quantitative Result.**Pretest Condition**: No fasting required; patients should be transplant recipients or candidates.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on donor mismatch, prior rejection, sensitization events.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected DSA including graft loss, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret DSA levels within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or recent transfusion can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Positive DSA indicates high rejection risk, necessitating specialist input.**Specialist Consultation**: Transplant nephrologists/immunologists should be consulted for management.**Additional Supporting Tests**: Crossmatch, C1q binding for confirmation.**Test Limitations**: Detects HLA-specific DSA; comprehensive approach required.**References**: Indian Journal of Transplantation 2024, Transplant Studies India 2023. |
